Chargement de la fiche…
Chargement de la fiche…
Hospitalo-universitaire
Photo : Ian42, CC BY-SA 3.0, Wikimedia Commons
Vous êtes Pr Patrick Mismetti ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.
Configurer votre fiche gratuitement →Pr Patrick Mismetti est rhumatologue à Saint-Priest-en-Jarez (42277). Il consulte à HOPITAL NORD - CHU42, Avenue ALBERT RAIMOND, 42277 Saint-Priest-en-Jarez.
Consulter
HOPITAL NORD - CHU42
Avenue ALBERT RAIMOND, 42277 Saint-Priest-en-Jarez
Hospitalier
Pr Patrick Mismetti, c'est vous ?
Faites de cette fiche la page de votre cabinet.
Pour aller plus loin
Remboursement
Pratique
Thèmes de publication
Domaines déduits des publications référencées sur PubMed.
Faits issus de registres publics et des déclarations du praticien — aucun classement.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'études spécialisées
DE Docteur en médecine — Capacité / certificat d'études spéciales
Les plus citées
2022Chest146 citations
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial
2025The New England journal of medicine137 citations
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
2022Frontiers in immunology134 citations
Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
En bref
Pr Patrick Mismetti consulte à HOPITAL NORD - CHU42, Avenue ALBERT RAIMOND, 42277 Saint-Priest-en-Jarez. Adresses issues de l'Annuaire Santé (ANS).
Par téléphone au 04 77 82 80 02 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.
Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.
Autour du cabinet
Rhumatologues à Saint-Priest-en-Jarez →Rhumatologues en Loire (42) →
Vous pouvez aussi demander le retrait de la fiche.
Aperçu de votre présentation
Rhumatologue à Saint-Priest-en-Jarez, j'accompagne…
Exemple : vous choisissez vos propres domaines.
Et pour votre consultation, gratuitement
2026The European respiratory journalPubMed
Comparative Safety and Efficacy of Apixaban and Rivaroxaban During Extended Anticoagulation for Venous Thromboembolism: A Non-randomised Post Hoc Comparison Within the RENOVE Trial
2026CirculationPubMed
Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial
2026The Lancet. HaematologyPubMed
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
2025Lancet (London, England)PubMed
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
2023NEJM evidencePubMed
Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients
2023EClinicalMedicinePubMed
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
2022ChestPubMed
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial
2025Archives of cardiovascular diseasesPubMed
The management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group
2024Archives of cardiovascular diseasesPubMed
Anticoagulant treatment of cancer-associated thromboembolism
2024Archives of cardiovascular diseasesPubMed
Management of cancer-associated thromboembolism: Introduction
2024Archives of cardiovascular diseasesPubMed
Management of cancer-associated thromboembolism in vulnerable population
2024Archives of cardiovascular diseasesPubMed
Cancer-related arterial thromboembolic events
2026Anaesthesia, critical care & pain medicinePubMed
Procedure-specific bleeding risk assessment: a multidisciplinary expert consensus companion to the 2026 periprocedural anticoagulant management guidelines
2025Anaesthesia, critical care & pain medicinePubMed
Anticoagulant management in Emergency settings: 2024 guidelines from the French Society of Emergency Medicine (SFMU), the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Working Group on Perioperative Haemostasis (GIHP), endorsed by the French Neurovascular Society
2024Anaesthesia, critical care & pain medicinePubMed
Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network
2023Respiratory medicine and researchPubMed
French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update
2024Presse medicale (Paris, France : 1983)PubMed
Elderly patients with venous thromboembolism: Insights from the RIETE registry
2022American journal of cardiovascular drugs : drugs, devices, and other interventionsPubMed
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
2026The European respiratory journalPubMed
Comparative Safety and Efficacy of Apixaban and Rivaroxaban During Extended Anticoagulation for Venous Thromboembolism: A Non-randomised Post Hoc Comparison Within the RENOVE Trial
2022American journal of cardiovascular drugs : drugs, devices, and other interventionsPubMed
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
2026 · Article
Comparative Safety and Efficacy of Apixaban and Rivaroxaban During Extended Anticoagulation for Venous Thromboembolism: A Non-randomised Post Hoc Comparison Within the RENOVE Trial
2026 · Article
Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis
2026 · Article
Procedure-specific bleeding risk assessment: a multidisciplinary expert consensus companion to the 2026 periprocedural anticoagulant management guidelines
2026 · Article
Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial
2026 · Congrès
OC 41.1 Recurrent venous thromboembolism during extended apixaban therapy for cancer-associated thrombosis: clinical presentation and short-term outcomes. Insights from the API-CAT proepective randomised double-blind trial
2025 · Article
Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study
2025 · Article
Apixaban or rivaroxaban for extended anticoagulation in patients with venous thromboembolism: A post hoc analysis of the renove clinical trial
2025 · Article
Role of platelet α2-adrenoreceptor in biological low response to Clopidogrel for patients with non cardioembolic ischemic stroke or transient ischemic attack
Publications affichées uniquement lorsque le nom du praticien figure parmi les auteurs. Une erreur d'homonymie ? Signalez-la depuis le lien en bas de page.
2001 · Lyon 1
Modélisation pharmacocinétique-pharmacodynamique par approche de population de deux antivitamines K, l'Acénocoumarol et la Warfarine : influence de l'éducation des malades et de l'observance au traitement sur la stabilité pharmacodynamique
1990 · Saint-Etienne
Interet de l'hemodilution normovolemique et de la section per-operatoire de l'arcade du soleaire : dans la prevention des thromboses veineuses profondes post-operatoires de la chirurgie du genou ; a propos d'un travail retrospectif portant sur 122 malades du service orthopedie du professeur g. bousquet a saint-etienne
2017 · doctorant : Farès Moustafa
Risque hémoragique sous anticoagulants : Vers une prise en charge personnalisée
2013 · doctorant : Marianne Sarazin
Elaboration d'un score de vieillissement : propositions théoriques
2011 · doctorant : Cyrille Renaud
L'infarctus cérébral artériel du nouveau-né à terme : présentation clinique, facteurs de risques et déterminants évolutifs à partir d'une cohorte prospective multicentrique d'épidémiologie descriptive
2011 · doctorant : Laurent Bertoletti
Prise en charge diagnostique et thérapeutique des patients suspects d'embolie pulmonaire : problématique particulière en cas de Broncho-Pneumopathie Chronique Obstructive
2010 · doctorant : Alice Lorans
Dénutrition en cancérologie : repérage des patients à risque
2009 · doctorant : Céline Chauleur
Identification des facteurs de risque pour prévenir les complications thrombotiques et hémorragiques de la grossesse